Mesoblast Ltd
Change company Symbol lookup
Select an option...
MESO Mesoblast Ltd
FBP First Bancorp
PTCT PTC Therapeutics Inc
ROKU Roku Inc
WORK Slack Technologies Inc
ARKW ARK Next Generation Internet ETF
SPOT Spotify Technology SA
GBTC Grayscale Bitcoin Trust (BTC)
ARKK ARK Innovation ETF
ARKG ARK Genomic Revolution ETF
Go

Health Care : Biotechnology | Mid Cap Growth
Based in Australia
Company profile

Mesoblast Limited is engaged in the development of regenerative medicine products. The Company’s regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. Its allogeneic, off-the-shelf cell product candidates target advanced stages of diseases with high and unmet medical needs. The Company’s portfolio of Phase III product candidates comprises RYONCIL (remestemcel-L) for steroid-refractory acute graft versus host disease (acute GVHD), REVASCOR for advanced chronic heart failure (CHF) and MPC-06-ID for chronic low back pain due to degenerative disc disease. The Company's product candidate, MPC-150-IM, is in Phase III trials for the treatment of both advanced and end-stage CHF. The Company has conducted Phase II trial of MPC-300-IV in patients with biologic-refractory rheumatoid arthritis. The Company is developing MPC-25-Osteo for spinal fusion.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Closing Price
$9.72
Day's Change
-0.11 (-1.12%)
Bid
--
Ask
--
B/A Size
--
Day's High
10.36
Day's Low
9.58
Volume
(Light)
Volume:
906,327

10-day average volume:
1,872,815
906,327

Display:

Providers:

UpdateCancel
6 providers
January 11, 2021
Mesoblast Presents Heart Failure Phase 3 Trial Results at Investor Healthcare Conference

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that its Chief Executive Officer, Dr Silviu Itescu, today presented additional data from the landmark DREAM-HF Phase 3...(Globe Newswire)

January 10, 2021
Single Dose of Rexlemestrocel-L Provides Substantial and Durable Reduction in Heart Attacks, Strokes and Cardiac Death in Patients With Chronic Heart Failure

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced additional results from the landmark DREAM-HF randomized controlled Phase 3 trial in 537 treated patients with...(Globe Newswire)

December 17, 2020
Mesoblast Webcast - Update on COVID-19 ARDS Trial

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast today to provide an update on the randomized controlled trial of remestemcel-L in ventilator-dependent patients...(Globe Newswire)

Mesoblast Update on COVID-19 ARDS Trial

Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today provided an update on the randomized controlled trial of remestemcel-L in ventilator-dependent patients with moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection...(Globe Newswire)

December 14, 2020
Mesoblast Provides Topline Results From Phase 3 Trial of Rexlemestrocel-L for Advanced Chronic Heart Failure

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced top-line results from the landmark DREAM-HF Phase 3 randomized controlled trial of its allogeneic cell therapy...(Globe Newswire)

Mesoblast Corporate Update

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast today to provide a corporate update. The webcast will begin at 9.00am AEDT, Tuesday, December 15; 5.00pm EST...(Globe Newswire)

December 07, 2020
MESO ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of December 7, 2020 in the Class Action Filed on Behalf of Mesoblast Limited Limited Shareholders

New York, New York--(Newsfile Corp. - December 7, 2020) -  The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Mesoblast Limited (NASDAQ: MESO) alleging that the Company violated federal securities...(Newsfile)

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of MESO, LOOP and LVS

NEW YORK, NY / ACCESSWIRE / December 7, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you...(Accesswire)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Mesoblast Limited of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 7, 2020 - MESO

New York, New York--(Newsfile Corp. - December 7, 2020) - The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Mesoblast Limited ("Mesoblast") (NASDAQ...(Newsfile)

DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Mesoblast Limited and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - December 7, 2020) -  The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Mesoblast Limited ("Mesoblast" or "the Company") (NASDAQ...(Newsfile)

MESO Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Mesoblast Limited Investors of Class Action and Lead Plaintiff Deadline: December 7, 2020

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Mesoblast Limited ("Mesoblast" or "the Company") (NASDAQ: MESO) and certain of its officers, on behalf of...(Globe Newswire)

MESO Final Deadline Today: Rosen, Leading Trial Attorneys, Reminds Mesoblast Limited Investors of Important December 7 Deadline in Securities Class Action - MESO

New York, New York--(Newsfile Corp. - December 7, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mesoblast Limited (NASDAQ: MESO) between April 16, 2019 and October 1, 2020, inclusive (the "Class...(Newsfile)

CLASS ACTION UPDATE for MESO, TRQ and BRY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, NY / ACCESSWIRE / December 7, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff...(Accesswire)

Remestemcel-L Reduces Inflammatory Biomarkers Predictive of High Mortality in Acute Graft Versus Host Disease

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced results presented at the 62 annual meeting American Society of Hematology (ASH), which provide in vivo biomarker...(Globe Newswire)

December 05, 2020
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Mesoblast Limited of Class Action Law Suit and Upcoming Deadline - MESO

Pomerantz LLP announces that a class action lawsuit has been filed against Mesoblast Limited ("Mesoblast" or the "Company") (NASDAQ: MESO) and certain of its officers. The class action, filed in United States District Court for the Southern...(PR Newswire)

MESO FINAL DEADLINE MONDAY: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Reminds Mesoblast Limited Investors of Important December 7 Deadline in Securities Class Action - MESO

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mesoblast Limited (NASDAQ: MESO) between April 16, 2019 and October 1, 2020, inclusive (the "Class Period"), of the important December 7, 2020 lead plaintiff...(BusinessWire)

December 04, 2020
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Mesoblast Limited and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of investors that...(BusinessWire)

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of RCL, MESO and PINS

NEW YORK, NY / ACCESSWIRE / December 4, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the...(Accesswire)

DEADLINE MONDAY ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Mesoblast Limited and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - December 4, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Mesoblast Limited (NASDAQ: MESO) ("Mesoblast" or "the...(Newsfile)

Lawsuits Filed Against MESO, LVS and YY - Jakubowitz Law Pursues Shareholders Claims

NEW YORK, NY / ACCESSWIRE / December 4, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods...(Accesswire)

Next >

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.